isatuximab-irfc

View Patient Information

A humanized IgG1 monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Isatuximab-irfc specifically binds to CD38 on CD38-positive tumor cells. This may trigger antitumoral antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and apoptosis eventually leading to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	isatuximab
US brand name:	Sarclisa
Code name:	Hu 38SB19 SAR 650984 SAR650984
Chemical structure:	immunoglobulin G1, anti-(human CD38 antigen) (human-mus musculus monoclonal HU38SB19 heavy chain), disulfide with human-mus musculus monoclonal HU38SB19 light chain, dimer

isatuximab-irfc

Search NCI's Drug Dictionary